Overview

Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant

Status:
Completed
Trial end date:
2020-03-05
Target enrollment:
Participant gender:
Summary
Proof of concept, open-label single center study for the donation of HCV positive kidneys to HCV negative patients, with preemptive, interventional treatment to prevent HCV transmission upon transplantation.
Phase:
Phase 4
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Grazoprevir